Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.

× No keyword cloud information.

6 in total

1. Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR).

Authors: Eric Tram; Irada Ibrahim-Zada; Laurent Briollais; Julia A Knight; Irene L Andrulis; Hilmi Ozcelik
Journal: Breast Cancer Res Date: 2011-08-11 Impact factor: 6.466

2. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.

Authors: Esther H Lips; Nadja Laddach; Suvi P Savola; Marieke A Vollebergh; Anne M M Oonk; Alex L T Imholz; Lodewyk F A Wessels; Jelle Wesseling; Petra M Nederlof; Sjoerd Rodenhuis
Journal: Breast Cancer Res Date: 2011-10-27 Impact factor: 6.466

3. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.

Authors: Shinichiro Kashiwagi; Masakazu Yashiro; Tsutomu Takashima; Naoki Aomatsu; Katsumi Ikeda; Yoshinari Ogawa; Tetsuro Ishikawa; Kosei Hirakawa
Journal: Breast Cancer Res Date: 2011-11-30 Impact factor: 6.466

PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.

1. Identification of germline alterations of the mad homology 2 domain of SMAD3 and SMAD4 from the Ontario site of the breast cancer family registry (CFR).

2. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.

3. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.

4. Comment on 'The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer'.

5. Biomarkers for Basal-like Breast Cancer.

6. Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer.